- Conditions
- Inherited Retinal Degeneration, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Location Directory
Clinical trials in Pittsburgh, Pennsylvania
This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10627
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 349–360 of 10,627 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Institutions in Pittsburgh
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Obesity
- Interventions
- survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 153
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more
- Conditions
- Quality of Life, Anxiety Postoperative
- Interventions
- Lavender peppermint elequil aromatab, Sweet almond oil elequil aromatab
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Retinitis Pigmentosa, Eye Diseases
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 13
- States / cities
- San Francisco, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Best Practice, Financial Navigation, Interview, Survey Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- Not listed
- Enrollment
- 760 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 383
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 252 more
- Conditions
- Coronary Artery Disease
- Interventions
- [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
- Drug
- Lead sponsor
- MedTrace Pharma A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo
- Drug
- Lead sponsor
- Bicara Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Camonsertib, Computed Tomography, Positron Emission Tomography, Stereotactic Body Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 4
- States / cities
- Duarte, California • Irvine, California • Lexington, Kentucky + 1 more
- Conditions
- Organic Acidemia, Methylmalonic Acidemia, Inborn Errors of Metabolism
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 115 Years
- Enrollment
- 2,275 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more
- Conditions
- Left Atrial Appendage Exclusion
- Interventions
- Penditure™ Left Atrial Appendage (LAA) Exclusion System
- Device
- Lead sponsor
- Medtronic Cardiac Surgery
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Carmel, Indiana + 12 more
- Conditions
- Pouchitis, Pouches, Ileoanal, Pouch, Ileal
- Interventions
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more